Generic Name and Formulations:
Aflibercept 40mg/mL; soln for oph intravitreal inj; preservative-free.
Indications for EYLEA:
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME).
Give by intravitreal injection. AMD: 2mg (0.05mL) once every 4 weeks (monthly) for the 1st 3 months, followed by 2mg (0.05mL) once every 8 weeks. RVO: 2mg (0.05mL) once every 4 weeks (monthly). DME: 2mg (0.05mL) once every 4 weeks (monthly) for the 1st 5 injections, followed by 2mg (0.05mL) once every 8 weeks (2 months).
Recombinant fusion protein (human VEGF inhibitor + human IgG1).
Ocular or periocular infections. Active intraocular inflammation.
Potential risk of arterial thromboembolic events (eg, nonfatal stroke or MI, vascular death). Monitor for endophthalmitis and retinal detachments during the week following injection. Monitor intraocular pressure and perfusion of optic nerve head after injection. Pregnancy (Cat.C). Nursing mothers: not recommended.
Conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, increased intraocular pressure, conjunctival hyperemia, corneal erosion, inj site pain, foreign body sensation in eye.
Vial (for single eye use)—1 (w. needles + syringe)
- 0.05ml of 2mg/0.05ml vials (Qty:1)
- appx. price $1896.00
- Over 50 FDA-Approved Meds Could Treat Ebola Infection
- Pharmacy Employees Arrested, Charged in Meningitis Outbreak
- How Effective Are Neuraminidase Inhibitors in Containing Flu?
- Ondansetron, Tramadol Drug Interaction Identified
- Pain Management in Patients with IBD: Individualizing Treatment Approaches